Scott graduated from University College London in 1999 with a PhD in Genetics and moved to the Brunel Institute for Cancer Genetics and Pharmacogenomics at Brunel University (London) where he conducted postdoctoral research in the identification of tumour suppressor genes. In 2002 he moved to the Wellcome Trust Centre for Human Genetics in Oxford to work on the genetics of heart disease. He joined Oxford BioMedica in 2006 to start an 11 year career in gene and cell therapy Product Development and was ultimately responsible for R&D of the Companys product pipeline as Head of Early Development. During this time he saw preclinical programmes progress into the clinic for chronic ocular conditions such as wet age-related macular degeneration, Stargardt disease and Usher syndrome. Scott started at Gyroscope Therapeutics in November 2017 where he is responsible for the development of the Companys early pipeline programmes, from target identification through to IND-enabling studies, as well as the development of new vector technologies as VP Preclinical Ophthalmology.